PureTech Health plc
NASDAQ:PRTCBiotechnology
+$0.45 today
- Market cap
- $423.09M
- Beta
- 0.79
- P/E (TTM)
- -0.4
- EPS (TTM)
- -$45.37
Volume 0.01M
Average 0.01M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
PureTech Health plc
NASDAQ:PRTC
Intrinsic Alpha fair value
Locked
Current Price
$17.38
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +30.6% | +366.8% (3yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +30.6% over three years. Forward estimates point to Revenue at +366.8% (3yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Alumis Inc. Common Stock NASDAQ:ALMS | $3.54B | $28.66 | Not rated | -12.2 | -24.49% |
Solid Biosciences Inc. NASDAQ:SLDB | $679.38M | $8.72 | Not rated | -4.3 | +39.37% |
Neurogene Inc. NASDAQ:NGNE | $589.58M | $37.31 | Not rated | -7.1 | +8.15% |
Autolus Therapeutics plc NASDAQ:AUTL | $383.25M | $1.44 | Not rated | -1.4 | -15.50% |
Rocket Pharmaceuticals, Inc. NASDAQ:RCKT | $375.63M | $3.44 | Not rated | -1.7 | -28.23% |
Benitec Biopharma Inc. NASDAQ:BNTC | $335.44M | $12.78 | Not rated | -12.3 | -39.76% |
Neumora Therapeutics, Inc. Common Stock NASDAQ:NMRA | $298.31M | $1.61 | Not rated | -1.2 | -87.42% |
Lineage Cell Therapeutics, Inc. AMEX:LCTX | $289.19M | $1.16 | Not rated | -4.6 | -53.91% |
ADC Therapeutics S.A. NYSE:ADCT | $171.71M | $1.35 | Not rated | -1.2 | -66.25% |
Quantum-Si incorporated NASDAQ:QSI | $162.69M | $0.82 | Not rated | -2.1 | -20.47% |
Continue the stock analysis
Jump to another research area for this company.